Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 01/23 09:49:14 pm
61.8846 USD   -1.03%
01/20 MERCK : Announces Settlement and License Agreement Resolving KEYTRUD..
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 DOW MOVERS : Ge, mrk
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:29am CET

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

 
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
01/20 MERCK : Announces Settlement and License Agreement Resolving KEYTRUDA® (pembroli..
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 DOW MOVERS : Ge, mrk
01/19 STUDIES FROM MERCK & COMPANY PROVIDE : PCSK9 as an...
01/19 MERCK : Reports Outline Pharmacology and Toxicology Study Findings from Merck & ..
01/19 MERCK : Researchers at Merck & Company Discuss Findings in Bioanalysis (Reductio..
01/19 INCYTE : and Merck to Advance Clinical Development Program Investigating the Com..
01/19 MERCK : Recent Findings from Merck & Company Advance Knowledge in Bioanalysis (A..
01/19 MERCK : to Participate at the 35th Annual J.P. Morgan Healthcare Conference
01/19 RESEARCHERS AT MERCK & COMPANY TARGE : A Powerful...
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:36p BIOTECH FORUM DAILY DIGEST : : Opdivo's Setback - Focus Feature On Fibrogen
02:48p Roche Challenges Keytruda's Colorectal Cancer Pole Position
01:51p ABBVIE : Leveraging Partnerships Play
11:09a Bristol Catches A Break At Last
06:37a BRISTOL-MYERS : An Activist Shows Up, Finally
Advertisement
Financials ($)
Sales 2016 39 928 M
EBIT 2016 13 699 M
Net income 2016 5 950 M
Debt 2016 3 965 M
Yield 2016 2,97%
P/E ratio 2016 30,04
P/E ratio 2017 17,70
EV / Sales 2016 4,42x
EV / Sales 2017 4,37x
Capitalization 172 404 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,2 $
Spread / Average Target 9,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.6.22%172 404
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.0.39%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
SANOFI-1.66%104 532
More Results